NCT00785941View on ClinicalTrials.gov

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

November 30, 2007

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

IMC-A12

"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"

BIOLOGICAL

IMC-A12

"Cohort 2~10 mg/kg I.V., once every other week for 4 weeks"

BIOLOGICAL

IMC-A12

"Cohort 3~15 mg/kg I.V., once every other week for 4 weeks"

BIOLOGICAL

IMC-A12

"Cohort 4~21 mg/kg I.V., once every other week for 4 weeks"

BIOLOGICAL

IMC-A12

"Cohort 5~27 mg/kg I.V., once every other week for 4 weeks"

Trial Locations (1)

37232

ImClone Investigational Site, Nashville

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00785941 - A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available | Biotech Hunter | Biotech Hunter